The physiological innovation of iron

Although effective, the currently available oral iron therapies could present tolerability limitations, with gastrointestinal side effects that negatively affect patient adherence and, consequently, overall treatment effectiveness. These challenges represent a significant clinical issue, especially in more vulnerable patients, and require solutions that better balance absorption, efficacy, and tolerability while respecting the intestinal bacterial flora.

The integration of new therapeutic strategies, based on innovative approaches, can significantly improve treatment adherence and ensure a more effective clinical response. In this context, tolfer®, a product based on IHAT™ (Iron Hydroxide Adipate Tartrate), represents true physiological innovation in the management of iron deficiency.

IHAT™ is the first and only nanoparticle-based novel food approved by EFSA (EFSA Scientific Opinion n. 27/10/2021), recognized by the European Commission as a new source of iron (Commission Implementing Regulation (EU) 2022/1373 of 5/8/2022; Official Journal EU n. 2024/248). This recognition attests its bioavailability and safety profile.

IHAT™ in the world

According to EU Authorization:

It’s recommended to take one capsule of the product per day at any time, regardless of meals. Products with an equivalent of 30 mg of iron shouldn’t be consumed by children and adolescents under 18 years of age. In the case of Tolfer™ DEMI (with an equivalent of 14 mg of iron), the product shouldn’t be consumed by children under 4 years of age. The use of food supplements isn’t intended as a substitute for a varied diet and a healthy lifestyle. Keep out of the reach of children under 3 years of age.